Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small-cell Lung Cancer (NSCLC)

Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138

Chatziandreou, 2015, Comprehensive molecular analysis of NSCLC; clinicopathological associations, PLoS One, 10, e0133859, 10.1371/journal.pone.0133859

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X

Yang, 2015, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol, 16, 141, 10.1016/S1470-2045(14)71173-8

Gainor, 2013, Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer, J Clin Oncol, 31, 3987, 10.1200/JCO.2012.45.2029

Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137

Salama, 2008, An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease, Clin Cancer Res, 14, 5255, 10.1158/1078-0432.CCR-08-0358

Inoue, 2010, Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions, Jpn J Clin Oncol, 40, 788, 10.1093/jjco/hyq044

Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study, Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0

Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375

Du, 2015, Chemotherapy for advanced-stage non-small cell lung cancer, Cancer J, 21, 366, 10.1097/PPO.0000000000000141

Yu, 2013, Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors, J Thorac Oncol, 8, 346, 10.1097/JTO.0b013e31827e1f83